当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
Cinryze, C1 Esterase Inhibitor (Human)
申请企业
ViroPharma Biologics LLC
药品名称
Cinryze, C1 Esterase Inhibitor (Human)
承诺描述
ViroPharma will re-test the available samples retained from Phase 3 Study (Protocol 0624-301) with the new immunogenicity assay and will submit the results of the study in a “Postmarketing Submission - Final Study Report” by January 1, 2020.
报告接收日期
2019/12/11 0:00:00